中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
23期
74-75
,共2页
复方苦参注射液%拉米夫定%慢性乙型肝炎
複方苦參註射液%拉米伕定%慢性乙型肝炎
복방고삼주사액%랍미부정%만성을형간염
Compound matrine injection%Lamivudine%Chronic hepatitis B
目的 探讨复方苦参注射液联合拉米夫定治疗慢性乙型肝炎的临床疗效.方法 选取2012年8月至2013年9月于驻马店市中心医院治疗的126例慢性乙型肝炎患者,将其随机分为对照组和观察组,每组63例,两组均予以常规治疗,对照组加用拉米夫定治疗,观察组加用复方苦参注射液联合拉米夫定治疗,分析对比两组患者的临床治疗效果.结果 对照组HBV-DNA转阴37例,占58.7％,观察组52例,占82.5％,观察组明显高于对照组(P＜0.05).结论 采用复方苦参注射液联合拉米夫定治疗慢性乙型肝炎疗效显著,可有效提高患者HVV-DNA转阴率,值得广泛应用推广.
目的 探討複方苦參註射液聯閤拉米伕定治療慢性乙型肝炎的臨床療效.方法 選取2012年8月至2013年9月于駐馬店市中心醫院治療的126例慢性乙型肝炎患者,將其隨機分為對照組和觀察組,每組63例,兩組均予以常規治療,對照組加用拉米伕定治療,觀察組加用複方苦參註射液聯閤拉米伕定治療,分析對比兩組患者的臨床治療效果.結果 對照組HBV-DNA轉陰37例,佔58.7％,觀察組52例,佔82.5％,觀察組明顯高于對照組(P＜0.05).結論 採用複方苦參註射液聯閤拉米伕定治療慢性乙型肝炎療效顯著,可有效提高患者HVV-DNA轉陰率,值得廣汎應用推廣.
목적 탐토복방고삼주사액연합랍미부정치료만성을형간염적림상료효.방법 선취2012년8월지2013년9월우주마점시중심의원치료적126례만성을형간염환자,장기수궤분위대조조화관찰조,매조63례,량조균여이상규치료,대조조가용랍미부정치료,관찰조가용복방고삼주사액연합랍미부정치료,분석대비량조환자적림상치료효과.결과 대조조HBV-DNA전음37례,점58.7％,관찰조52례,점82.5％,관찰조명현고우대조조(P＜0.05).결론 채용복방고삼주사액연합랍미부정치료만성을형간염료효현저,가유효제고환자HVV-DNA전음솔,치득엄범응용추엄.
Objective To investigate the clinical efficacy of compound matrine injection combined with lamivudine on chronic hepatitis B.Methods One hundred and twenty-six cases of chronic hepatitis B patients were selected from 2012 August to 2013 September in our hospital.They were randomly divided into control group and observation group,each group had 63 cases.The two groups were both given regular treatment.And the control group was treated with lamivudine,the observation group was treated with Compound Kushen injection combined with lamivudine.The clinical therapeutic effects of the two groups were compared.Results In the control group,37 patients with negative HBV-DNA,accounting for 58.7％.In the observation group,52 patients with HBV-DNA negative,accounting for 82.5％.The HBV-DNA negative rate in observation group was significantly higher than that in the control group (P ＜ 0.05).Conclusions Compound matrine injection combined with lamivudine in the treatment of chronic hepatitis B were significantly.It can effectively improve the patients with HVV-DNA negative rate,and is worthy of wide application.
